<DOC>
	<DOC>NCT02718937</DOC>
	<brief_summary>The primary purpose of this study is to evaluate the antiviral activity of oral BTA-C585 compared to placebo in healthy volunteers after intranasal challenge with RSV-A Memphis 37b virus.</brief_summary>
	<brief_title>Safety, Efficacy and Pharmacokinetics of BTA-C585 in a RSV Viral Challenge Study</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<criteria>1. Healthy male or female 2. Between 18 to 50 years old 3. Body mass index of 18 to 30 kg/m2 1. Acute or chronic medical illness 2. Abnormal lung function Positive for HIV, Hepatitis B or C 3. Any significant abnormality of the nose or nasopharynx</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Viral diseases</keyword>
	<keyword>Antiviral</keyword>
	<keyword>Paramyxoviridae infections</keyword>
	<keyword>RSV</keyword>
	<keyword>Aviragen Therapeutics, Inc.</keyword>
	<keyword>Aviragen Therapeutics</keyword>
	<keyword>Aviragen</keyword>
</DOC>